MARKET

CPIX

CPIX

Cumberland
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.390
0.000
0.00%
After Hours: 3.370 0 0.00% 16:00 07/28 EDT
OPEN
3.410
PREV CLOSE
3.390
HIGH
3.490
LOW
3.336
VOLUME
31.83K
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
2.580
MARKET CAP
50.72M
P/E (TTM)
-10.1905
1D
5D
1M
3M
1Y
5Y
Cumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
/PRNewswire/ -- Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental, social and governance (ESG) matters.
PR Newswire - PRF · 2d ago
Daqo New Energy's subsidiary Xinjiang Daqo completes its IPO Registration with China Securities Regulatory Commission
Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy", the "Company" or "we"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, is in the process of applying for an initial public offering ("IPO") of the Company's major ope...
PR Newswire · 06/22 13:15
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
Zacks · 06/22 10:46
Cumberland Pharmaceuticals Says Co's Vibativ Helps Treat Secondary Bacterial Infections In COVID-19 Patients
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial
Benzinga · 06/21 13:23
BRIEF-Cumberland Pharma- Released Series Of Case Reports Describing Effectiveness Of Vibativ In Treating Secondary Bacterial Infections In Covid-19 Patients
reuters.com · 06/21 13:21
Cumberland Pharmaceuticals, Inc. (CPIX): Are Hedge Funds Right About This Stock?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 06/18 15:56
United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag
United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.
Zacks · 06/17 13:40
RAPT, SIOX, ACHL and PTGX among after-hours movers
Gainers: [[RAPT]] +25.2%. [[SIOX]] +13.5%. [[ELOX]] +13.2%. [[DOGZ]] +9.9%. [[CPIX]] +7.4%.Losers: [[ACHL]] -10.1%. [[PTGX]] -7.4%. [[TCDA]] -6.5%. [[NGMS]] -6.1%. [[VRM]] -4.6%.
Seekingalpha · 06/14 21:40
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPIX. Analyze the recent business situations of Cumberland through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPIX stock price target is 8.50 with a high estimate of 8.50 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 3.43M
% Owned: 22.79%
Shares Outstanding: 15.05M
TypeInstitutionsShares
Increased
7
161.04K
New
5
41.39K
Decreased
7
663.66K
Sold Out
2
188.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.13%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Chairman/Chief Executive Officer/Director
A. Kazimi
Chief Financial Officer/Finance Director
John Hamm
Executive Vice President/Director
Martin Cearnal
Executive Vice President
Leo Pavliv
Chief Compliance Officer/Vice President
James Herman
Independent Director
Gordon Bernard
Independent Director
Joseph Galante
Independent Director
Jonathan Griggs
Independent Director
Joey Jacobs
Independent Director
James Jones
Independent Director
Kenneth Krogulski
Independent Director
Caroline Young
No Data
About CPIX
Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Webull offers kinds of Cumberland Pharmaceuticals, Inc. stock information, including NASDAQ:CPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPIX stock methods without spending real money on the virtual paper trading platform.